The NeuroGraph™

A 510(k) cleared, non-invasive medical device

Diagnosis is a vitally important tool in treatments directed at psychiatric disorders. Most diagnostic procedures, however, are still subjective and often time-consuming.  Accordingly, psychiatrists and other mental heath care professionals desire a rapid, objective method to add to their standard diagnosis techniques.  In response to this need Thuris developed a simple, fast, and non-invasive electrophysiological procedure for identifying mental disorders. The turnkey system includes user-friendly hardware and interface software as well as proprietary analytical algorithms. In addition to Alzheimer’s Disease and Mild Cognitive Impairment, the Company is targeting Huntington’s disease, selected headache syndromes, and schizophrenia; trials involving ADHD are planned.

NeuroGraph - Diagnostic Uses

510(k) marketing clearance from FDA has been won “As an aide in the diagnosis of Central Nervous System disorders”.

Currently, typical workups for MCI and/or Alzheimer’s disease take many days and cost thousands of dollars. The NeuroGraph’s initial screen can be performed in only about 20 minutes, and at a fraction of the cost. The NeuroGraph not only adds a needed objective measure to subjective diagnostic methods, but also creates a revenue source for the doctors who use it.  Initial market research indicates that the NeuroGraph will become a widely-used aid to psychiatrists and neurologists, helping them make more accurate diagnoses and monitor the effect of drug regimes on their patients. 

NeuroGraph - Clinical Trial Uses

The NeuroGraph will be offered to pharmaceutical and biotechnology companies for use in Central Nervous System clinical trials.  The system can be used to address two of the most significant issues in CNS trials - 1) homogenous patient groups for enrollment and, 2) objective endpoints.